S&P 500   3,011.95 (+0.17%)
DOW   26,912.80 (+0.32%)
QQQ   193.10 (-0.15%)
AAPL   241.52 (+0.42%)
FB   183.53 (-3.28%)
MSFT   137.61 (-0.59%)
GOOGL   1,246.12 (+0.15%)
AMZN   1,771.74 (-0.78%)
CGC   20.82 (+2.31%)
NVDA   196.23 (+0.11%)
BABA   170.92 (-1.50%)
TSLA   257.05 (+1.40%)
AMD   31.75 (-0.87%)
T   38.28 (+0.13%)
ACB   3.61 (-2.17%)
NFLX   269.67 (-3.01%)
BAC   31.25 (+0.74%)
GILD   66.33 (+1.72%)
DIS   133.55 (+2.53%)
S&P 500   3,011.95 (+0.17%)
DOW   26,912.80 (+0.32%)
QQQ   193.10 (-0.15%)
AAPL   241.52 (+0.42%)
FB   183.53 (-3.28%)
MSFT   137.61 (-0.59%)
GOOGL   1,246.12 (+0.15%)
AMZN   1,771.74 (-0.78%)
CGC   20.82 (+2.31%)
NVDA   196.23 (+0.11%)
BABA   170.92 (-1.50%)
TSLA   257.05 (+1.40%)
AMD   31.75 (-0.87%)
T   38.28 (+0.13%)
ACB   3.61 (-2.17%)
NFLX   269.67 (-3.01%)
BAC   31.25 (+0.74%)
GILD   66.33 (+1.72%)
DIS   133.55 (+2.53%)
Log in

Osmotica Pharmaceuticals Stock Price, News & Analysis (NASDAQ:OSMT)

$4.43
-0.31 (-6.54 %)
(As of 10/22/2019 01:20 PM ET)
Today's Range
$4.31
Now: $4.43
$4.73
50-Day Range
$2.96
MA: $3.81
$4.75
52-Week Range
$2.20
Now: $4.43
$9.75
Volume6,000 shs
Average Volume70,467 shs
Market Capitalization$228.23 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex ANDAs and other ANDAs for various treatments. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OSMT
CUSIPN/A
CIKN/A
Phone908-809-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$263.70 million
Cash Flow$3.08 per share
Book Value$7.50 per share

Profitability

Net Income$-109,400,000.00

Miscellaneous

Employees466
Market Cap$228.23 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive OSMT News and Ratings via Email

Sign-up to receive the latest news and ratings for OSMT and its competitors with MarketBeat's FREE daily newsletter.


Osmotica Pharmaceuticals (NASDAQ:OSMT) Frequently Asked Questions

What is Osmotica Pharmaceuticals' stock symbol?

Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."

How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) announced its quarterly earnings results on Thursday, August, 8th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.06. The business had revenue of $57.53 million for the quarter, compared to analyst estimates of $57.90 million. Osmotica Pharmaceuticals had a negative return on equity of 32.14% and a negative net margin of 97.91%. View Osmotica Pharmaceuticals' Earnings History.

When is Osmotica Pharmaceuticals' next earnings date?

Osmotica Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Osmotica Pharmaceuticals.

What price target have analysts set for OSMT?

4 brokerages have issued 12-month price targets for Osmotica Pharmaceuticals' shares. Their forecasts range from $10.00 to $17.00. On average, they expect Osmotica Pharmaceuticals' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 193.5% from the stock's current price. View Analyst Price Targets for Osmotica Pharmaceuticals.

What is the consensus analysts' recommendation for Osmotica Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Osmotica Pharmaceuticals.

Has Osmotica Pharmaceuticals been receiving favorable news coverage?

Press coverage about OSMT stock has been trending negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Osmotica Pharmaceuticals earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Osmotica Pharmaceuticals.

Are investors shorting Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals saw a decline in short interest during the month of September. As of September 15th, there was short interest totalling 163,400 shares, a decline of 21.4% from the August 15th total of 207,900 shares. Based on an average trading volume of 108,700 shares, the days-to-cover ratio is presently 1.5 days. Approximately 2.3% of the shares of the stock are short sold. View Osmotica Pharmaceuticals' Current Options Chain.

Who are some of Osmotica Pharmaceuticals' key competitors?

What other stocks do shareholders of Osmotica Pharmaceuticals own?

Who are Osmotica Pharmaceuticals' key executives?

Osmotica Pharmaceuticals' management team includes the folowing people:
  • Mr. Brian A. Markison, Chairman, Pres & CEO (Age 60)
  • Mr. Andrew J. Einhorn, Chief Financial Officer (Age 59)
  • Dr. Tina Marie deVries, Exec. VP of R&D (Age 58)
  • Mr. James D. Schaub, Exec. VP & COO (Age 37)
  • Mr. Christopher A. Klein, Gen. Counsel & Sec. (Age 55)

When did Osmotica Pharmaceuticals IPO?

(OSMT) raised $58 million in an IPO on Thursday, October 18th 2018. The company issued 8,300,000 shares at a price of $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.

How do I buy shares of Osmotica Pharmaceuticals?

Shares of OSMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Osmotica Pharmaceuticals' stock price today?

One share of OSMT stock can currently be purchased for approximately $4.43.

How big of a company is Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals has a market capitalization of $228.23 million and generates $263.70 million in revenue each year. The company earns $-109,400,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Osmotica Pharmaceuticals employs 466 workers across the globe.View Additional Information About Osmotica Pharmaceuticals.

What is Osmotica Pharmaceuticals' official website?

The official website for Osmotica Pharmaceuticals is http://www.osmotica.com/.

How can I contact Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-809-1300 or via email at [email protected]


MarketBeat Community Rating for Osmotica Pharmaceuticals (NASDAQ OSMT)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  116
MarketBeat's community ratings are surveys of what our community members think about Osmotica Pharmaceuticals and other stocks. Vote "Outperform" if you believe OSMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: What is a death cross?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel